Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

  PMID 41997138 · PMC13213619 · Cancer cell · 2026 · 8 claims · 8 setups

  Full-text index only

  A novel proliferative Treg precursor state, cycling Treg (cycTreg: FOXP3^int, MKI67^hi, IKZF2/4^int-hi), is absent in normal breast, low in DCIS, and strongly expanded in IBC

  normal mammary dcis tumor-draining scrna-seq spatial multiplex

• FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-α.

  PMID 40619383 · PMC12229025 · Cellular & molecular biology letters · 2025 · 8 claims · 8 setups

  Has reproduction · 73

  Low FRMD8 expression in BRCA1-mutant breast cancer cells significantly enhances metastatic potential to various organs

  tnbc geo breast frmd8 bulk meta-analysis single-cell

• A hormetic transcriptional program coregulates invasion, proliferation and dormancy to define metastatic potential.

  PMID 41781391 · PMC13077004 · Nature communications · 2026 · 8 claims · 7 setups

  Full-text index only

  Prrx1 is a master regulator of dissemination that, beyond promoting invasion, represses proliferation (via Ccnd1/2, Cdkn2a/b/c) and activates a dormancy program (Gas6, Mme, Ogn)

  infiltrating metabric facs-sorted pymt immunohistochemistry bioinformatic rt-qpcr

• Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

  PMID 41484081 · PMC12858953 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Combined low-dose CTX + anti-CSF-1R (SNDX-ms6352) is highly effective against aggressive metastatic Trp53-null TNBC models with high macrophage infiltration, producing complete tumor regression in claudin-low models.

  trp53-null complete t12 cell-deficient imaging survival tumor